Pharma Solutions / Clinical Trial Endpoint

About HepQuant

HepQuant is a commercial-stage diagnostics company focused on transforming the management of liver disease through its proprietary, noninvasive blood test, HepQuant DuO. The test quantitatively measures liver function and portal blood flow, providing a Disease Severity Index to help clinicians stratify risk and manage patients with chronic liver conditions like cirrhosis and MASH. The company operates a CLIA lab, markets its test as a Laboratory Developed Test (LDT), and is also targeting the pharmaceutical sector for use in clinical trials. With a large addressable market of over 100 million Americans with some form of liver disease, HepQuant aims to become a standard tool in hepatology.

Therapeutic Areas